Since their introduction, IVIG have been proposed as a treatment for an array of disorders, including primary and secondary immune deficiency states, and a variety of autoimmune and inflammatory disorders.

It is suggested that IVIG (0.2 g to 2.0 g per kg bodyweight, any regimen) might have beneficial effects on the pathogenic processes of Alzheimer’s disease {20}, also at the stage of Mild Cognitive Impairment, by interfering positively with metabolism of amyloid β that seems to be reduced in subjects at risk for Alzheimer’s disease. It is hypothesised that IVIG use for passive immunotherapy in Alzheimer’s disease could slow the disease progression {20} {46} and use in patients with Mild Cognitive Impairment could avoid or delay the onset of Alzheimer’s disease {Appendix SAF-1}.